We evaluated the potential therapeutic potential of targeting PRKDC to enhance the efficacy of immunotherapy and confirmed the potential therapeutic options involving the use of PRKDC inhibitors combined with anti-PD-1 therapy for melanoma treatment in the future. Here, PDCD1 is linked to melanoma.